Cureous Labs, a forward-thinking medtech startup aiming to transform patient care and nursing efficiency, has successfully raised Rs 1.66 crore in a recent seed funding round. The investment
Cureous Labs, a forward-thinking medtech startup aiming to transform patient care and nursing efficiency, has successfully raised Rs 1.66 crore in a recent seed funding round. The investment was led by Inflection Point Ventures (IPV) with additional backing from Anthill Ventures.
This funding marks a significant milestone for the startup as it prepares to scale the manufacturing and distribution of its flagship innovation—Eturnal, India’s first retrofittable automatic patient repositioning system designed to prevent pressure injuries, commonly known as bedsores.
Bedsores and pressure injuries remain a persistent and expensive challenge in hospitals and long-term care facilities. These injuries not only diminish patient well-being but also impose a significant burden on caregivers and hospital resources.
Cureous Labs aims to change that. Its Eturnal system offers advanced pressure relief by automatically repositioning bedridden patients at regular intervals, a task that is traditionally manual and physically demanding for caregivers. According to the company, this breakthrough reduces caregiver injuries while significantly improving patient outcomes.
What makes Eturnal even more notable is its cost-effectiveness. Priced at just one-fifth the cost of international alternatives, the product is poised to deliver value at scale, especially for Indian healthcare institutions that are often restricted by budget constraints.
The newly raised capital will be deployed across key growth areas:
This multifaceted plan is expected to not only drive business growth but also solidify Cureous Labs’ reputation as an innovator in patient-centric healthcare technology.
The product development journey for Eturnal is backed by over two years of clinical research, combining insights from 100+ hospitals in India and Australia. Cureous Labs worked closely with healthcare professionals to understand the day-to-day challenges of managing immobile patients and preventing pressure injuries, incorporating this feedback into the design and function of their technology.
The startup’s focus on clinical relevance, combined with real-world applicability and user-friendly design, positions it strongly in the Indian medtech space.
Cureous Labs’ innovation addresses a critical yet often overlooked aspect of healthcare—automating routine yet vital care tasks. By removing the manual burden from caregivers and introducing consistency in patient positioning, the solution not only enhances patient safety but also allows healthcare staff to focus on more complex tasks.
Moreover, the affordability and retrofittable nature of Eturnal make it an inclusive solution, particularly for mid- and small-tier hospitals that might otherwise be unable to afford such technology.
As Cureous Labs moves into this next growth phase, the healthcare community will be watching closely. The startup’s ability to deliver on manufacturing, scale B2B operations, and expand its product line will determine how broadly it can impact the Indian healthcare landscape.
With the support of Inflection Point Ventures and Anthill Ventures, Cureous Labs is now well-positioned to become a leading force in hospital automation, pressure injury prevention, and cost-effective patient care.
